Revenue Recognition - Collaboration and License Agreement (Details)		3 Months Ended		6 Months Ended
	Nov. 22, 2020 USD ($) Program	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Deferred revenue, revenue recognized		$ 20,628,000	$ 22,303,000	$ 37,382,000	$ 40,599,000
BMS | Collaboration and License Agreement
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Upfront fee received	$ 55,000,000.0
Maximum milestone payments to be received	$ 2,700,000,000
Number of programs under agreement | Program	5
Transaction price	$ 55,000,000.0
Deferred revenue, revenue recognized		700,000	$ 5,400,000	28,800,000	$ 9,400,000
Deferred revenue		21,700,000		21,700,000		$ 25,500,000
Receivable from collaboration		$ 0		0		$ 8,000,000.0
BMS | Collaboration and License Agreement | Oncology Product
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Maximum milestone payments to be received	585,000,000.0
Milestone payments to be received upon achievement of certain specified research, development, and regulatory milestones	360,000,000.0
Milestone payments to be received upon achievement of certain specified commercial milestones	225,000,000.0
BMS | Collaboration and License Agreement | Neurology and Immunology Product
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Maximum milestone payments to be received	489,000,000.0
Milestone payments to be received upon achievement of certain specified research, development, and regulatory milestones	264,000,000.0
Milestone payments to be received upon achievement of certain specified commercial milestones	$ 225,000,000.0
BMS | Collaboration and License Agreement | Oncology, Neurology, and Immunology Product
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Deferred revenue, revenue recognized				$ 25,000,000.0